HC Wainwright reiterated their buy rating on shares of BioLineRx (NASDAQ:BLRX – Free Report) in a report issued on Tuesday, Benzinga reports. They currently have a $21.00 price target on the biotechnology company’s stock. Separately, StockNews.com upgraded shares of BioLineRx to a sell rating in a report on Monday, December 4th. View Our Latest Research […]

Related Keywords

, Renaissance Technologies , Biolinerx Ltd , Envestnet Asset Management Inc , Asset Management Corp , Atria Wealth Solutions Inc , Biolinerx Company Profile , Free Report , Wealth Solutions , Asset Management , Management Corp , Get Free Report , Linerx Ltd , Biolinerx Daily ,